The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines "CSL's growing R&D presence in Waltham is the latest example of our ...
The U.S. FDA clearance June 16 of CSL Behring LLC’s humanized anti-factor XIIa monoclonal antibody garadacimab (CSL-312) to prevent hereditary angioedema (HAE) attacks juiced up the space in which – ...
The Food and Drug Administration has approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor ...
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hemophilia A and B Recombinant Factor Replacement Therapy - Current and Future Players" report to their offering. The ...
WALTHAM, Mass., March 27, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC:CSLLY) today celebrated the official opening of the company's new state-of-the-art research and ...
No articles found. CSL Behring Canada did not contribute to any primary research papers from Nature Index journals in the current 12 month window. The following affiliated institutions are wholly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results